Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / ZLAB - Paratek Zai Labs up on Chinese approval of Nuzyra for pneumonia skin infections


ZLAB - Paratek Zai Labs up on Chinese approval of Nuzyra for pneumonia skin infections

Paratek Pharmaceuticals (PRTK +12.2%) is up 12% after announcing that China's National Medical Products Administration approved Nuzyra (omadacycline) for community-acquired bacterial pneumonia and bacterial skin infections. Nuzyra was licensed to Zai Labs (ZLAB +15.7%) in greater China. As a result of the approval, Paratek received a $6M milestone payment. Read Seeking Alpha contributor Bret Jensen's take on Paratek.

For further details see:

Paratek, Zai Labs up on Chinese approval of Nuzyra for pneumonia, skin infections
Stock Information

Company Name: Zai Lab Limited
Stock Symbol: ZLAB
Market: NASDAQ
Website: zailaboratory.com

Menu

ZLAB ZLAB Quote ZLAB Short ZLAB News ZLAB Articles ZLAB Message Board
Get ZLAB Alerts

News, Short Squeeze, Breakout and More Instantly...